Emily D Pollock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily D Pollock has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anika Parker
Department of Epidemiology, School of Public Health, University of Washington , Seattle, Washington
1 shared publication- Bindy Crouch
Bureau of Immunization, New York City Department of Health and Mental Hygiene , New York, NY
1 shared publication - Christine M. Khosropour
Department of Epidemiology, University of Washington, Seattle, USA
1 shared publication - Enrique M. Saldarriaga
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, USA
1 shared publication - Ian H. Spicknall
Division of STD Prevention, National Center for HIV, Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention
1 shared publication - Ian Kracalik
Division of Healthcare Quality Promotion Centers for Disease Control and Prevention Atlanta Georgia USA
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Estimation of Antimicrobial-Resistant Mycoplasma genitalium Infections in People Aged 14–59 Years: Results From the National Health and Nutrition Examination Survey, United States, 2017–2018
Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10)
Open AccessEstimation of Antimicrobial-Resistant Mycoplasma genitalium Infections in People Aged 14–59 Years: Results From the National Health and Nutrition Examination Survey, United States, 2017–2018
Mycoplasma genitalium antimicrobial resistance is common in US sexual health clinics. Population-level prevalence is unknown. We tested National Health and Nutrition Examination Survey (2017–2018) specimens for M genitalium resistance mutations (n = 58). Macrolide resistance prevalence was 42.7% (95% CI, 24.4%–62.7%). Quinolone resistance was not detected. Macrolide resistance testing should guide azithromycin treatment.
- Open Access
- 11 March 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (4) , 948-955
Modeling the impact of vaccine dose prioritization strategies during the 2022 mpox outbreak
Early in the 2022 mpox outbreak, the US recommendation was to administer two doses of the JYNNEOS vaccine 4 weeks apart. However, because of limited vaccine supply, New York City (NYC) prioritized single dose vaccination. We estimated mpox cases averted by this strategy compared to strategies that prioritized 2-dose vaccination for a smaller portion of the population. We fit a network transmission model to incident mpox cases in NYC. Model output consisted of predicted cases over time when vaccine doses were administered with the “first-dose priority” strategy, compared with counterfactual simulations, where doses were administered to those eligible for a second dose ahead of those waiting for a first dose (“intermediate” strategy), or where individuals were preallocated full courses of the vaccine (“second-dose priority” strategy). We estimate that NYC’s strategy averted 66% (IQR, 47%-78%) of potential mpox cases compared to no vaccination. This “first-dose priority” strategy averted 0.6% (IQR, −11% to 9.8%) more cases than the “intermediate” strategy, and 17% (IQR, 2.9%-38%) more cases than the “second-dose priority” strategy. Thus, for the 2022 mpox outbreak in NYC, preallocating vaccine doses to ensure full vaccination in a high-priority subset of the population would have increased the size of the outbreak.
- 11 March 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (4) , 948-955
Open AccessModeling the impact of vaccine dose prioritization strategies during the 2022 mpox outbreak
Early in the 2022 mpox outbreak, the US recommendation was to administer two doses of the JYNNEOS vaccine 4 weeks apart. However, because of limited vaccine supply, New York City (NYC) prioritized single dose vaccination. We estimated mpox cases averted by this strategy compared to strategies that prioritized 2-dose vaccination for a smaller portion of the population. We fit a network transmission model to incident mpox cases in NYC. Model output consisted of predicted cases over time when vaccine doses were administered with the “first-dose priority” strategy, compared with counterfactual simulations, where doses were administered to those eligible for a second dose ahead of those waiting for a first dose (“intermediate” strategy), or where individuals were preallocated full courses of the vaccine (“second-dose priority” strategy). We estimate that NYC’s strategy averted 66% (IQR, 47%-78%) of potential mpox cases compared to no vaccination. This “first-dose priority” strategy averted 0.6% (IQR, −11% to 9.8%) more cases than the “intermediate” strategy, and 17% (IQR, 2.9%-38%) more cases than the “second-dose priority” strategy. Thus, for the 2022 mpox outbreak in NYC, preallocating vaccine doses to ensure full vaccination in a high-priority subset of the population would have increased the size of the outbreak.